Drug intelligence / Profile preview

caffeine + carisoprodol + diclofenac + paracetamol

Development stage
Unknown
Lead developer
Ache Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

A fixed-dose combination medication containing **caffeine**, **carisoprodol**, **diclofenac**, and **paracetamol (acetaminophen)**. This formulation is intended for the treatment of **pain and inflammation** of various etiologies. - **Caffeine** acts as a central nervous system stimulant and is sometimes included to enhance the analgesic effects of other agents. - **Carisoprodol** is a centrally acting muscle relaxant used to relieve muscle spasms associated with acute musculoskeletal conditions. - **Diclofenac** is a nonsteroidal anti-inflammatory drug (NSAID), primarily acting as a cyclooxygenase (COX) inhibitor, thereby reducing inflammation and pain. - **Paracetamol (Acetaminophen)** is an analgesic and antipyretic, believed to act mainly in the central nervous system by inhibiting prostaglandin synthesis. The combination is not widely approved or standard in many regions; fixed-dose combinations of multiple analgesics and muscle relaxants are more typical in certain countries for short-term management of acute pain, though concerns exist about additive toxicity and potential for adverse effects[1][2][4].

Brand names
Tandrilax
Other names
diclofenac sodium + carisoprodol + paracetamol + caffeine
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)KMO (Kynurenine 3-monooxygenase)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGES (Microsomal prostaglandin E synthase-1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)ADORA1 (Adenosine receptor A1 subtype)CNR1 (Cannabinoid receptor 1)GABRR (GABA-A receptor subunit rho)COX-3 (Mitochondrially encoded cytochrome c oxidase subunit 3)

Beyond the preview

Go deeper on caffeine + carisoprodol + diclofenac + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on caffeine + carisoprodol + diclofenac + paracetamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call